title: Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.
abstract: OBJECTIVE
  No investigation has been conducted on the association between PET findings and serum Cyfra 21.1 and CEA levels in nonsmall cell lung cancers (NSCLC). The purpose of this study is to find out if the serum levels of Cyfra 21.1 and CEA are related to metabolic parameters by FDG PET in patients with NSCLC who had not received treatment.
  
  
  METHODS
  Seventy-six NSCLC patients, who were admitted for initial staging by FDG PET/CT, were included in the study. Serum Cyfra 21.1 and CEA levels were assayed by enzyme-linked immunosorbent assay. FDG-PET images were analyzed with visual and quantitative methods. Standard uptake values (SUV), metabolic tumor volumes (MTV) and total lesion glycolysis were calculated for primary lesion (T) and whole-body lesions (primary and metastatic) (WB).
  
  
  RESULTS
  Serum Cyfra 21.1 and CEA level was significantly higher in patients with locoregionally advanced disease (p < 0.05, p < 0.05, respectively) and metastatic disease (p < 0.01, p < 0.05, respectively) compared to those with localized disease. The serum ln-Cyfra-21.1 was significantly correlated with all volumetric tumor parameters (p < 0.001) and slightly with ln-SUVmean.WB (p < 0.05). There was no relationship between CEA levels and any PET metabolic parameters (p > 0.05). In multiple linear regression analysis incorporating ln-MTV.WB and ln-SUVmean.WB as independents, ln-MTV.WB correlated significantly and positively with ln-Cyfra-21.1 (β = 0.744, p < 0.001), whereas ln-SUVmean.WB did not significantly predict ln-Cyfra-21.1 (β = 0.019, p > 0.05).
  
  
  CONCLUSIONS
  This study demonstrates the existence of a significant relationship between total tumor burden and the serum Cyfra 21.1 level in NSCLC patients who had not received treatment. However, it requires further confirmation in operated NSCLC patients.
authors.affiliation: Department of Nuclear Medicine, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey, drismaildogan@yahoo.com.
authors.forename: Ismail
authors.initials: I
authors.lastname: Dogan
authors.forename: Savas
authors.initials: S
authors.lastname: Karyagar
authors.forename: Sevda Saglampinar
authors.initials: SS
authors.lastname: Karyagar
authors.forename: Cemil
authors.initials: C
authors.lastname: Kahraman
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alver
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000000981:diagnostic imaging; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000000981:diagnostic imaging*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000000981:diagnostic imaging; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006019:Glycolysis; D006801:Humans; D053539:Keratin-19 / Q000097:blood*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed; D047368:Tumor Burden
chemical_list: D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; C102012:antigen CYFRA21.1